Ophthalmology

However, data show RVO patients with clinical findings associated with glaucoma risk are often not coded with suspected glaucoma.

A new assessment from ARVO 2022 showed methodology to predict one-year treatment response to treat-and-extend ranibizumab at 1 year.

The study agent was otherwise not associated with an increased number of intravitreal injections over a 12-month period.

Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.

Patients with DR had an average interval between anti-VEGF injections of 70 days, compared to 54 days for RVO patients and 55 days for wetAMD patients.

The Elevatum trial will assess the newly approved ophthalmic drug in patients from African American, Hispanic, Latin American, and Indigenous communities.

One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.

An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.

The estimated median duration of ≥1 line gained was greater than 9 hours on both study day 1 and day 30 in patients with presbyopia treated with the study agent.

A new cohort analysis suggest one-year intravitreal treatment burden can be significantly reduced when patients are only administered brolucizumab.

Data suggest baseline vision was a key predictor of poor response at Week 24 in patients with macular edema secondary to central retinal vein occlusion.

New research found veterans with diabetes who took L-DOPA and dopamine agonists showed delayed onset of vascular pathology associated with DR.

A new contribution of data evidences the "controversial" use of concomitant steroids in patients who do not benefit from monotherapy anti-VEGF.

A new study shows BCVA scores and blood levels of AA/EPA significantly improved in treated patients with dry AMD or Stargardt disease at 24 weeks.

An investigation into the diffusion, capacity and drug concentrations showed predictable flexibility with the novel ophthalmic implant device.

Matthew Cunningham, MD, explains the need for greater inclusion of impacted races and ethnicities in ophthalmic clinical trials.

Data show Black individuals had a 1.41 times higher odds of having type 2 diabetic retinopathy when compared to white individuals.

Future epidemiologic studies may be necessary to investigate further using perinatal data and controlling for other variables.

Nancy Holekamp, MD discusses the substantial emotional burden and impact on independence of GA reported in the Geographic Atrophy Insights Survey.

71.6% of patients showed a clinically meaningful improvement in total corneal fluorescein staining at 4 weeks after using the ophthalmic solution.

Dexamethasone as a first-line treatment for DME may increase economic costs in settings where bevacizumab is used off-label, but lower annual costs compared with aflibercept.

Data show visual display terminal use causes dry eye disease mainly through impaired blinking patterns.

Pregnant women with preexisting T1D or T2D had a higher rate of any DR and a higher DR progression rate compared to the nonpregnant population.

However, initially observed eyes were found more at risk of developing moderate visual loss and more than 80% required treatment over 24 months.

Socioeconomic factors beyond race and ethnicity may play important role in determining prematurity and ROP risk.

Investigators noted selection bias and unaccounted-for confounders may make the increase in RVO incidence coincidental to COVID-19 infection.

Data show at-home VA test results from printed chart, mobile phone app, and website were validated within 1 line to in-office measurements.

The study shows fenofibrate use was associated with a lower risk of progression to PDR and VTDR, but not DME alone.

Data show a combined increase in the risk of SRD, RVO, and ION associated with the use of PDE5Is in older men.

Mean follow-up IOP was similar between groups, with a median of 15.83 mm Hg among patients with glaucoma versus 14.94 mm Hg among healthy participants.